Laibah Arshad Khan

Dr. Laibah Arshad Khan


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2024 in Cardiac Failure Review
Verified
Journal Article
Open access
PDF file
LKLaibah Arshad Khan
Laibah Arshad Khan
AJAdeena Jamil
Adeena Jamil
SGStephen J Greene
Stephen J Greene
Muhammad Shahzeb KhanMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
JBJaved Butler
Javed Butler
Aldosterone is a key regulator of fluid and electrolyte balance in the body. It is often dysregulated in heart failure (HF) and is a key driver of cardiac remodelling and worse clinical outcomes. Potassium regulation is essential for normal cardiac, gastrointestinal and neuromuscular function. Serum potassium fluctuations are largely determined by aldosterone, the final step of the renin–angiotensin–aldosterone system. Dyskalaemia (i.e. hypokalaemia and hyperkalaemia) is prevalent in HF because of the disease itself, its therapies and related comorbidities such as chronic kidney disease. Prognostic implications of abnormal serum potassium follow a U-shaped curve, where both hypokalaemia and hyperkalaemia are associated with adverse outcomes. Hypokalaemia is associated with increased mortality, starting from potassium <4.0 mmol/l but especially at potassium <3.5 mmol/l. Hyperkalaemia, along with increasing arrhythmia risk, limits the use of lifesaving renin–angiotensin–aldosterone system inhibitors, which may have long-term survival implications. The advent of novel potassium binders aims to manage chronic hyperkalaemia and may allow for uptitration and optimal dosing of guideline-recommended therapy. This review discusses the impacts of dyskalaemia in HF, along with management strategies, including the relevance of potassium binder use in optimising HF treatment. Current and potential future aldosterone-modulating therapies, such as non-steroidal mineralocorticoid receptor antagonists and aldosterone synthase inhibitors, are also discussed.

21 June 2025 in American Heart Journal
Verified
Journal Article
Closed access
MHMuhammad Hanif
Muhammad Hanif
LKLaibah Arshad Khan
Laibah Arshad Khan
AKAnandita Kulkarni
Anandita Kulkarni
HBHarpreet S. Bhatia
Harpreet S. Bhatia
MWMichael J. Wilkinson
Michael J. Wilkinson
MKMuhammad Shahzeb Khan
Muhammad Shahzeb Khan

30 September 2025 in Global Cardiology
Verified
Journal Article
Open access
PDF file
LKLaibah Arshad Khan
Laibah Arshad Khan
SJSyed Sarmad Javaid
Syed Sarmad Javaid
JBJaved Butler
Javed Butler
Iron deficiency (ID) is present in 30-80% of patients with heart failure (HF) and is associated with poor prognosis. Intravenous (IV) iron therapy has been evaluated in several randomized controlled trials and consistently shown to improve functional outcomes. In FAIR-HF, 50% of patients receiving FCM achieved NYHA class improvement to I or II by 24 weeks vs 30% with placebo. CONFIRM-HF showed a significant 33-meter increase in 6-minute walk distance (6MWD) at 24 weeks (p=0.002), alongside improvements in NYHA class. The recent trial FAIR-HF2 demonstrated smaller but significant gains in 6MWD (+10.7 m) and global well-being at 12 months. Cardiovascular outcomes have been more variable. AFFIRM-AHF showed a 26% reduction in total HF hospitalizations (HR 0.74; 95% CI, 0.58-0.94) with IV iron vs placebo. Although the composite of cardiovascular death or first HF hospitalization was narrowly non-significant (HR 0.79; 95% CI, 0.62-1.01), the effect may still be clinically meaningful. IRONMAN, using ferric derisomaltose vs placebo, was neutral for the primary endpoint of HF hospitalization and cardiovascular death (RR 0.82; 95% CI, 0.66-1.02) but showed benefit in a COVID-censored sensitivity analysis (RR 0.76; 95% CI, 0.58-1.00). In HEART-FID, involving over 3,000 patients, no benefit was also seen with IV iron for the composite of death, HF hospitalization, and 6MWD at 99% CI, however was significant at 95% CI. FAIR-HF2 showed a 21% reduction in the primary endpoint (HR 0.79; 95% CI 0.61-1.02) with IV iron, which did not meet statistical significance, but a prespecified 12-month sensitivity analysis demonstrated a 29% reduction in first cardiovascular death or HF hospitalization (0.71 (95% CI, 0.53-0.94) and a 35% reduction in total HF hospitalizations (RR 0.65; 95% CI, 0.47-0.90). The most recent meta-analysis (n>7,000) showed a 28% reduction of composite of cardiovascular death and HF hospitalizations at 1 year (RR 0.72; 95% CI, 0.55-0.89) with IV iron. Benefits were sustained at longer term follow up and were consistent across most subgroups. The totality of evidence supports IV iron in HFrEF with ID to improve symptoms and reduce HF hospitalizations, especially in the first year. Future research should explore optimal long-term dosing, sex-specific responses, and the role of IV iron in HF with preserved ejection fraction.

30 June 2025 in Global Cardiology
Verified
Journal Article
Open access
PDF file
WRWardah Rasool
Wardah Rasool
ASAhmed Kamal Siddiqi
Ahmed Kamal Siddiqi
LKLaibah Arshad Khan
Laibah Arshad Khan
Patient-reported outcomes (PROs) are increasingly recognized as pivotal tools in understanding health status, treatment impact, and quality of life (QoL) in patients, particularly those with chronic cardiovascular diseases. These standardized and validated tools capture the patient’s perspective on physical, emotional, and social health dimensions, bridging gaps often missed by clinical evaluations. Despite their growing adoption in research, the use of PROs in new drug approvals has declined, from 30% between 1997–2002 to 16.5% between 2011–2015, raising concerns about their underutilization in real-world settings. However, their role in clinical care and research continues to expand, with the proportion of clinical trials incorporating PROs increasing from 14% between 2004–2007 to 27% between 2007–2013. PRO measures (PROMs) span multiple domains, including overall health, such as EQ-5D, SF-36, and PROMIS Profile-29 to evaluate health-related quality of life (HRQoL), psychological health, evaluated by instruments like the Patient Health Questionnaire-9 (PHQ-9), specific symptoms, such as pain and fatigue, functional status, and disease-specific outcomes such as the Kansas City Cardiomyopathy Questionnaire (KCCQ-12). The clinical impact of PROs is evident in their association with prognostic outcomes. Each 5-point decrease in the KCCQ score correlates with a 6–9% higher risk of cardiovascular death or heart failure hospitalization. Meta-analyses reveal that higher HRQoL reduces mortality risk by 37% (HR 0.633, 95% CI: 0.514–0.780). Additionally, in pre-terminal cancer patients, self-reported abilities to walk 4 meters and wash oneself independently predicted survival, hazard ratios of 0.63 (p=0.015) and 0.67 (p=0.024), respectively. Moreover, in chronic obstructive pulmonary disease, pain and discomfort predicted re-hospitalization and HRQoL predicted 180-day survival. These findings underscore the critical role of PROs in enhancing patient care, guiding therapeutic decisions, and shaping healthcare policies.

1 September 2025 in Global Cardiology
Verified
Journal Article
Open access
PDF file
LKLaibah Arshad Khan
Laibah Arshad Khan
MHMuhammad Hanif
Muhammad Hanif
ARAhmed Mustafa Rashid
Ahmed Mustafa Rashid
Lipoprotein(a) [Lp(a)] is a plasma particle structurally similar to LDL, distinguished by the presence of apolipoprotein(a), and has evolved from plasminogen. Lp(a) concentration is 90% genetically determined and largely stable throughout life. Black individuals exhibit the highest Lp(a) levels, followed by South Asians, Whites, Hispanics, and East Asians, with a 2- to 4-fold median difference across ancestral groups. Approximately 1.5 billion people worldwide (~20% of the population) have elevated Lp(a) levels (>125 nmol/L or >50 mg/dL). Notably, women experience 17% higher levels than men post-menopause. Mendelian randomization studies have established Lp(a) as a strong cardiovascular disease (CVD) risk factor, implicated in coronary artery disease, peripheral artery disease (PAD), ischemic stroke, heart failure, and aortic stenosis. Risk increases linearly with Lp(a) levels, with concentrations >90 mg/dL (>190 nmol/L) associated with a 1.6-fold higher risk of ischemic stroke, 1.7-fold for heart failure, 2-fold for PAD, and 3-fold for aortic stenosis and myocardial infarction. Lp(a) levels between 130–391 mg/dL (280–849 nmol/L) confer atherosclerotic CVD risk equivalent to familial hypercholesterolemia. Universal screening of once Lp(a) test is now recommended for all adults in guidelines across the US, Europe and Canada. However, Lp(a) testing is severely underutilized with studies showing 0.3% testing frequency amongst 5.5 million US patients. Even in high-risk patients with established ASCVD, only 13.9% are tested for Lp(a). Existing treatment options for elevated Lp(a) include proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and lipoprotein apheresis. Emerging therapies include antisense oligonucleotides such as pelacarsen, small-interfering RNA such as zerlasiran, olpasiran, and lepodisiran, and oral agents such as muvalaplin. These medications have shown a significant reduction in plasma levels up to 80% (pelacarsen), 96.9% (olpasiran), 97% (lepodisiran) and 99% (zerlasiran) in phase 1 and 2 trials, with larger studies ongoing to assess cardiovascular outcomes. With advancing therapies, clinician awareness, early detection, and risk management of Lp(a) are critical to improving outcomes.

11 December 2025 in Global Cardiology
Verified
Journal Article
Open access
PDF file
SBSyeda Sundus Shah Bokharii
Syeda Sundus Shah Bokharii
CVCristiana Vitale
Cristiana Vitale
EKEman Khan
Eman Khan
GRGiuseppe M.C. Rosano
Giuseppe M.C. Rosano
LKLaibah Arshad Khan
Laibah Arshad Khan
Coronary artery calcium (CAC) scoring, measured by computed tomography (CT), quantifies calcified coronary plaque and reflects the burden of coronary atherosclerosis. The Agatston score, calculated based on lesion density and area, stratifies patients into risk categories: a score of 0 indicates no detectable calcification, 1-99 suggests mild plaque, 100-399 indicates moderate burden, and scores of 400 or more reflect high to extensive calcification, with scores above 1000 indicate extremely high atherosclerotic burden. CAC scoring is most beneficial in asymptomatic adults aged 40 to 75 years with borderline (5-7.5%) or intermediate (7.5-20%) 10-year ASCVD risk when uncertainty exists regarding statin initiation. The Multi-Ethnic Study of Atherosclerosis (MESA) found that a CAC score of 0 significantly reduces estimated ASCVD risk compared to pooled cohort equation (PCE) predictions, with observed event rates of approximately 1.5% for borderline-risk and 4.5% for intermediate-risk individuals, supporting reclassification into a lower-risk category. Scores of 1-99 represent modestly elevated risk and may guide prevention based on clinical judgment and patient preference. Scores from 100 to 400 reflect moderate plaque burden and support statin therapy, while high scores above 400 reflect substantial atherosclerotic burden, mandating aggressive preventive interventions. CAC testing is generally not indicated in younger, low-risk adults, as they may develop ASCVD later in life, and a score of 0 could lead to false reassurance that discourages appropriate prevention. Similarly, testing is typically unnecessary in elderly individuals with established atherosclerotic disease, as results rarely change management. It is also not recommended in those with clear statin indications, including patients with diabetes, familial hyperlipidemia, existing ASCVD, or those already on lipid-lowering treatment. Frequent CAC retesting is discouraged due to limited clinical benefit, unnecessary costs, potential downstream testing, patient anxiety, and exposure to radiation, though repeating CAC after five years may be reasonable for those initially scoring zero. The recent CAUGHT-CAD trial showed that CAC-informed strategies reduced LDL cholesterol and slowed plaque progression in intermediate-risk individuals with familial coronary artery disease, highlighting its importance. Future research should focus on optimizing CAC use to enhance patient outcomes while balancing clinical utility, cost, and risk.